Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (original): A compound of formula I



I

wherein

R_a is H; CH_3; CH_2-CH_3; or isopropyl,

R_b is H; halogen; C_{1-6}alkoxy; or C_{1-6}alkyl, and either

I. R is a radical of formula (a)



(a)

wherein

R_1 is piperazin-1-yl optionally substituted by CH_3 in position 3 or 4; or 4,7-diaza-spiro [2.5] oct-7-yl;

R_2 is Cl; Br; CF_3; or CH_3; and

R_3 is H; CH_3; or CF_3; R_2 being other than CH_3 or Cl when R_3 is H, R_a is H or CH_3, R_b is H and R_1 is 4-methyl-1-piperazinyl; or

II. R is a radical of formula (b)



(b)

wherein

R_4 is piperazin-1-yl substituted in positions 3 and/or 4 by CH_3; or 4,7-diaza-spiro [2.5] oct-7-yl; R_a being other than H or CH_3 when R_4 is 4-methyl-1-piperazinyl; or

III. R is a residue of formula (c)



(c)

wherein

R_{14} is piperazin-1-yl optionally substituted by CH_3 in position 3 and/or 4 or in position 3 by ethyl, phenyl-C_{1-4}alkyl, C_{1-4}alkoxy-C_{1-4}alkyl or halogeno–C_{1-4}alkyl; or 4,7-diaza-spiro [2.5] oct-7-yl;

R_{15} is halogen; CF_3; or CH_3; R_{15} being other than CH_3 when R_{16} is CH_3, R_a is H or CH_3, R_b is H and R_{14} is 4-methyl-1-piperazinyl; and

R_{16} is H; CH_3; CH_2-CH_3; or CF_3; R_{16} being other than H when R_{15} is Cl, R_a is H or CH_3, R_b is H and R_{14} is 4-methyl-1-piperazinyl; or

IV. R is a radical of formula (d)



(d)

wherein

R_8 is 1-piperazinyl, 3-methyl-piperazin-1-yl or 4-benzyl-piperazin-1-yl; or

V. R is a radical of formula (e)



(e)

wherein

R_9 is 4,7-diaza-spiro [2.5] oct-7-yl; or 1-piperazinyl substituted in position 3 by methyl or ethyl and optionally in position 4 by methyl,

or a salt thereof.

Claim 2 (original): A compound according to claim 1 which is selected from 3-[5-chloro-6-methyl-2-(4- methyl-piperazin-1-yl)-pyrimidin-4-yl]-4-(1H-indol-3-yl)-pyrrole-2,5-dione, 3-[3-(4,7-diaza-spiro[2.5]oct-7-yl)-isoquinolin-1-yl]-4-(7-methyl-1H-indol-3-yl)-pyrrole-2,5-dione and 3-(1H-indol-3-yl)-4-[2-(4-methyl-piperazin-1-yl)-5-trifluoromethyl-pyrimidin-4-yl]pyrrole-2,5-dione or a salt thereof.

Claim 3 (original): A process for the preparation of a compound of formula I according to claim 1, which process comprises reacting a compound of formula II



(II)

wherein R_a and R_b are as defined in claim 1,

with a compound of formula III

$$R - CH_2 - CO - NH_2 \qquad (III)$$

wherein R is as defined in claim 1,

and, where required, converting the resulting compound of formula I obtained in free form to a salt form or vice versa, as appropriate.

Claim 4 (cancelled).

Claim 5 (previously presented): A pharmaceutical composition comprising a compound of formula I according to claim 1 or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable diluent or carrier therefor.

Claims 6 - 7 (cancelled) .

Claim 8 (original): A combination comprising a) a compound of formula I in free form or in pharmaceutically acceptable salt form, and b) at least one second agent selected from an immunosuppressant, immunomodulatory, anti-inflammatory, antiproliferative and anti-diabetic drug.

Claim 9 (currently amended): A method for ~~preventing or~~ treating disorders or diseases mediated by T lymphocytes and/or PKC or GSK-3β for the treatment of acute or chronic rejection of organ or tissue allo- or xenografts, graft versus host diseases, atherosclerosis, vascular occlusion due to vascular injury such as angioplasty, restenosis, obesity, syndrome X, impaired glucose tolerance, polycycstic ovary syndrome, hypertension, heart failure, chronic obstructive pulmonary disease, CNS diseases such as Alzheimer disease or amyotrophic lateral sclerosis, cancer, infectious diseases such as AIDS, septic shock or adult respiratory distress syndrome, ischemia/reperfusion injury such as myocardial infarction, stroke, gut ischemia, renal failure or hemorrhage shock or traumatic shock such as traumatic brain injury, in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a compound of formula I according to claim 1 or a pharmaceutically acceptable salt thereof.

Claim 10 (original): A method according to claim 9 comprising co-administration concomitantly or in sequence of a therapeutically effective amount of a compound of formula I in free form or in pharmaceutically acceptable salt form, and a second drug substance, said second drug substance being an immunosuppressant, immunomodulatory, anti-inflammatory, antiproliferative or anti-diabetic drug.